Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Isoray Inc (AAJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
0.3756-0.0006 (-0.16%)
At close: 08:04AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3762
Open0.3756
Bid0.3723 x 500000
Ask0.3938 x 500000
Day's Range0.3756 - 0.3756
52 Week Range0.2143 - 0.4380
Volume0
Avg. Volume30
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AAJ.SG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

      RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.

    • Zacks

      Profound Medical (PROF) Reports Q3 Loss, Lags Revenue Estimates

      Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    • GlobeNewswire

      Isoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022

      Conference Call is Thursday, November 10, 2022 at 4:30 p.m. ET/1:30 p.m. PTRICHLAND, Wash., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the first quarter fiscal 2023 ended September 30, 2022 on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time. The Company w

    Advertisement
    Advertisement